|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, February 17, 2017 ) Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects
Type 2 diabetes mellitus (T2DM) is a chronic, progressive and serious metabolic disorder characterized by hyperglycemia (high blood glucose levels) and associated with numerous complications and co-morbidities, including cardiovascular, renal and neurodegenerative diseases.
For more information about this report: http://www.reportsweb.com/frontier-pharma-type-2-diabetes-mellitus
Global prevalence of the disease has risen rapidly in the past several decades, primarily as a result of rising obesity, a major risk factor for T2DM. This has resulted in a large and competitive market landscape, with a number of drugs competing with one another for different market segments, across multiple lines of therapy.
The emergence over the past decade of glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors and sodium-glucose cotransporter 2 (SGLT-2) inhibitors has intensified competition. These new drug classes have been highly commercially successful and are now well established within the treatment algorithm.
In spite of these developments, there are still significant unmet needs for T2DM, and the rationale for investment in first-in-class innovation remains strong. First-in-class products account for a considerable proportion of the large T2DM pipeline, with a diverse range of first-in-class targets identified.
Scope
The escalating T2DM public healthcare need has resulted in a competitive market landscape
- What is the pathophysiology of T2DM?
- What are the common co-morbidities and complications?
- How has the emergence of new drug classes in the past decade impacted the treatment algorithm?
- What are the most significant unmet needs within the market?
The T2DM pipeline is large and innovative
- Which molecule types and molecular targets are most prominent within the pipeline?
- Which first-in-class targets are most promising?
- How does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class?
The T2DM deals landscape is highly active
- Do T2DM products attract high deal values?
- Which molecule types and molecular targets dominate the deals landscape?
- Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?
Request Sample Copy at http://www.reportsweb.com/inquiry&RW00020759/sample
Reasons to buy
This report will allow you to -
- Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, and treatment options.
- Identify leading products and companies within the market, as well as key unmet needs, in order to gain a competitive understanding of gaps in the current market.
- Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, all first-in-class targets in the T2DM pipeline have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
- Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.
Table of Contents
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 5
2.1 Large and Competitive Market Landscape Driven by Rising Prevalence 5
2.2 Investment in First-in-Class Innovation Remains Strong 5
2.3 Opportunities for Investment in First-in-Class Product Development are Considerable 5
3 The Case for Innovation 6
3.1 Growing Opportunities for Biologic Products 7
3.2 Diversification of Molecular Targets 7
3.3 Innovative First-in-Class Product Development Remains Attractive 7
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 8
3.5 Sustained Innovation 8
3.6 GBI Research Report Guidance 8
4 Clinical and Commercial Landscape 10
4.1 Disease Overview 10
4.2 Classification of Diabetes Mellitus 10
4.3 Symptoms 11
4.4 Epidemiology 11
4.5 Etiology 12
4.6 Pathophysiology 12
4.7 Co-morbidities and Complications 14
4.8 Management and Treatment of Type 2 Diabetes Mellitus 16
4.8.1 Non-insulin T2DM Therapies 17
4.9 Insulin-Based T2DM Therapies 20
4.10 Overview of Marketed Products in Type 2 Diabetes 21
4.11 Unmet Need and Commercial Opportunities in T2DM 24
5 Assessment of Pipeline Product Innovation 25
5.1 Pipeline by Stage of Development, Molecule Type and Molecular Target 25
5.2 Comparative Distribution of Programs between the Market and Pipeline by Molecular Target Class 29
5.3 First-in-Class Programs by Molecular Target Category 29
6 Type 2 Diabetes Mellitus Signaling Network, Disease Causation and Innovation Alignment 48
6.1 Complexity of Signaling Networks 48
6.2 Signaling Pathways and First-in-Class Molecular Target Integration 48
6.3 First-in-Class Matrix Assessment 48
7 First-in-Class Target and Pipeline Program Evaluation 54
7.1 Pipeline Programs Targeting Insulin Receptor Substrate 1 and Insulin Receptor Substrate 2 54
7.2 Pipeline Programs Targeting G-Protein Coupled Receptor Kinase 5 (GRK5) 56
7.3 Pipeline Programs Targeting Type 2 Angiotensin II Receptor 57
7.4 Pipeline Programs Targeting Islet Amyloid Polypeptide (IAPP) 58
7.5 Pipeline Programs Targeting Nacht LRR and PYD Domains Containing Protein 3 60
7.6 Pipeline Programs Targeting Peroxisome Proliferator Activated Receptor Gamma Coactivator 1 Alpha (PPARGC1A) 61
7.7 Pipeline Programs Targeting Glucagon 62
7.8 Pipeline Programs Targeting Alpha Synuclein 64
7.9 Pipeline Programs Targeting Microtubule Associated Protein Tau 65
8 Strategic Consolidations 67
8.1 Industry-Wide First-in-Class Deals 67
8.2 Licensing Deals 68
8.3 Co-development Deals 71
8.4 First-in-Class Programs Not Involved in Licensing or Co-development Deals 74
Inquire before Buying at http://www.reportsweb.com/inquiry&RW00020759/buying
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
